Sight Sciences (SGHT) Q3 2026 earnings summary

Executive summary

• Record Q3 revenue of $24.9M, up 25.2% YoY, with record Interventional Dry Eye revenue and continued Interventional Glaucoma growth.

• Net loss narrowed to $6.8M from $8.2M; FY26 revenue guidance was raised to $92M-$93M.

• Products have been used in over 500,000 procedures; strategy emphasizes earlier procedure-based care and shared glaucoma and dry eye practices and patients.

Financial highlights

• Q3 gross profit rose 24.6% to $21.4M; gross margin was 85.9% versus 86.4% a year earlier.

• Operating expenses rose 10% to $27.5M; adjusted OpEx was $24.0M, up 21%. SG&A rose to $24.8M, while R&D fell to $2.7M.

• Q3 net loss was $6.8M versus $8.2M; diluted loss per share was $0.12 versus $0.16.

• 9M revenue increased 19.4% to $68.0M; net loss narrowed to $24.2M from $34.3M.

Outlook and guidance

• FY26 revenue guidance raised to $92M-$93M from $88M-$92M, implying 19%-20% YoY growth; adjusted OpEx guidance maintained at $92M-$94M, up 5%-7%.

• FY26 Interventional Dry Eye revenue outlook raised to ~$12M from $9M-$11M; Interventional Glaucoma outlook is $80M-$81M.

• Management expects Interventional Glaucoma momentum to continue into Q4 and 2027; OMNI Ultra is expected to support growth. No 2027 guidance was given.

• Near-term Interventional Dry Eye priorities include scaling within First Coast and Novitas, growing accounts and utilization, and pursuing broader payer access; decision timing remains uncertain.